Sáez Barcelona J A, Carmona Martín M, Navarro López V, Blanch Sancho J J, Puras Tellaeche A
Hospital General de Albacete.
Rev Clin Esp. 1999 May;199(5):270-4.
Corticosteroid therapy has been shown to improve glucose tolerance in some connective tissue diseases. This fact has been inadequately investigated in vasculitis.
To evaluate the effect of glucocorticoid therapy on glucose tolerance in patients with temporal arteritis (TA) or polymyalgia rheumatica (PR).
An oral test with glucose overload (OGO) was performed before and after one month of initiating therapy with corticosteroids in 14 patients with TA or PR (TA/PR group) and in nine patients with other chronic inflammatory diseases (control group).
After treatment, patients with TA/PR experienced a decrease in the area under the glucose curve and in serum glucose values at minutes 0, 90, and 120 of the OGTT. Also, a decrease was observed for the area under the insulin curve and for plasma insulin levels at minutes 90 and 120 after OGO.
Therapy with corticosteroids improves glucose tolerance in TA/PR with no increase in insulin secretion.
皮质类固醇疗法已被证明可改善某些结缔组织疾病中的糖耐量。这一事实在血管炎中尚未得到充分研究。
评估糖皮质激素疗法对颞动脉炎（TA）或风湿性多肌痛（PR）患者糖耐量的影响。
对14例TA或PR患者（TA/PR组）和9例其他慢性炎症性疾病患者（对照组）在开始使用皮质类固醇治疗1个月前后进行口服葡萄糖耐量试验（OGO）。
治疗后，TA/PR组患者的葡萄糖曲线下面积以及口服葡萄糖耐量试验（OGTT）0、90和120分钟时的血糖值均降低。此外，口服葡萄糖耐量试验（OGO）后90和120分钟时，胰岛素曲线下面积和血浆胰岛素水平也有所降低。
皮质类固醇疗法可改善TA/PR患者的糖耐量，且不会增加胰岛素分泌。
